Diagnosing Urticaria: What to Expect at the Doctor
A thorough diagnosis is essential for effective management, particularly in chronic cases. Here is what a comprehensive evaluation typically involves:
Medical History
The most important diagnostic tool is a detailed medical history. A doctor or allergist will ask about:
- When the hives first appeared and how long episodes typically last
- Where on the body they most commonly occur
- Whether any pattern to timing is apparent (time of day, relation to meals, activities, seasons)
- Any potential triggers identified by the patient or family
- Current medications, including over-the-counter products and supplements
- Recent infections, vaccinations, or illnesses
- Family history of urticaria, allergies, or autoimmune conditions
- Any associated symptoms including angioedema, breathing difficulty, or systemic symptoms
Physical Examination
A dermatologist or allergist will examine the skin during an active episode and may use dermoscopy for a closer look. The distribution, size, and characteristics of the wheals provide important diagnostic information.
Allergy Testing
For suspected allergic urticaria:
Skin prick testing — small amounts of common allergens are introduced into the superficial skin layer. A positive reaction (localized wheal formation) indicates IgE-mediated sensitization to that allergen.
Specific IgE blood tests — serum testing for allergen-specific IgE antibodies provides an alternative to skin testing and may be preferred when skin testing carries risk or is not feasible.
Food elimination diets — when food allergens are suspected, systematic elimination and reintroduction under medical supervision can help identify specific triggers.
Laboratory Tests for Chronic Urticaria
In chronic urticaria, laboratory testing helps identify underlying conditions that may be contributing:
- Complete blood count (CBC) — identifies infections, eosinophilia, or anemia
- C-reactive protein and erythrocyte sedimentation rate — markers of systemic inflammation
- Thyroid function tests and thyroid antibodies — thyroid autoimmunity is associated with chronic urticaria in a significant proportion of cases
- Antinuclear antibodies (ANA) — screening for autoimmune conditions
- Hepatitis B and C serology — viral infections can trigger chronic urticaria
- H. pylori testing — this common stomach bacterium is associated with some cases of chronic urticaria
- Serum complement levels — to evaluate for hereditary angioedema
Challenge Tests for Inducible Urticaria
When physical urticaria is suspected, standardized challenge tests can confirm the diagnosis:
- Dermographometer test — standardized pressure is applied to skin to assess dermographism
- Ice cube test — an ice cube placed on the forearm for a defined period tests for cold urticaria
- UV light exposure testing — for suspected solar urticaria
- Exercise challenge — for suspected cholinergic urticaria
Treatment Options for Urticaria — From First Line to Advanced Therapies
The treatment landscape for urticaria has advanced significantly in recent years, with options ranging from simple antihistamines to targeted biological therapies for severe, refractory cases.
First-Line Treatment: Non-Sedating Antihistamines
Second-generation antihistamines are the cornerstone of urticaria management and the recommended first-line treatment by international dermatology and allergy guidelines. These include:
- Cetirizine (Zyrtec) — fast-acting, highly effective, available over the counter
- Loratadine (Claritin) — non-drowsy, appropriate for daytime use
- Fexofenadine (Allegra) — minimal sedation, effective for daily dosing
- Bilastine — newer generation with favorable efficacy and tolerability profile
- Desloratadine (Clarinex) — active metabolite of loratadine with good evidence base
Unlike first-generation antihistamines (diphenhydramine/Benadryl), second-generation options cause minimal sedation while still effectively blocking histamine H1 receptors. They work best when taken regularly rather than only during active outbreaks.
Updosing — taking up to four times the standard dose of second-generation antihistamines — is recommended by current international guidelines when standard dosing provides insufficient control in chronic urticaria. This approach is supported by evidence and is considered safe under medical supervision.
Second-Line Treatment: Adding H2 Antihistamines
H2 antihistamine receptors are found in the skin and gastrointestinal tract. Adding an H2 blocker — such as famotidine (Pepcid) or ranitidine — to H1 antihistamine therapy can provide additional benefit in some cases, particularly for urticaria with gastrointestinal involvement.
Third-Line Treatment: Omalizumab (Xolair) — The Biological Revolution
The introduction of omalizumab into urticaria treatment represents one of the most significant advances in managing chronic spontaneous urticaria in decades.
Omalizumab is a monoclonal antibody that binds to and neutralizes free IgE in the bloodstream. By reducing available IgE, it stabilizes mast cells and dramatically reduces their tendency to degranulate in response to triggers.
